Serious generalized pustular psoriasis with evolution to plaque psoriasis: approach with spesolimab

Generalized pustular psoriasis (GPP) is characterized by an acute and severe variant of psoriasis, often accompanied by systemic symptoms, with the eruption of multiple sterile pustules over an area of erythema, associated or not with the form of plaque psoriasis. Epidemiological data on disease are...

Full description

Saved in:
Bibliographic Details
Main Authors: Liz S. Gea, Julia C. K. El Dib, Omar Algazal, Eduardo C.N. Constantino, Vera L. A. Nasser, João R. Antonio
Format: Article
Language:English
Published: Sociedade Portuguesa de Dermatologia e Venereologia 2024-10-01
Series:Revista da Sociedade Portuguesa de Dermatologia e Venereologia
Subjects:
Online Access:https://www.portuguesejournalofdermatology.com/frame_eng.php?id=177
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850063531456593920
author Liz S. Gea
Julia C. K. El Dib
Omar Algazal
Eduardo C.N. Constantino
Vera L. A. Nasser
João R. Antonio
author_facet Liz S. Gea
Julia C. K. El Dib
Omar Algazal
Eduardo C.N. Constantino
Vera L. A. Nasser
João R. Antonio
author_sort Liz S. Gea
collection DOAJ
description Generalized pustular psoriasis (GPP) is characterized by an acute and severe variant of psoriasis, often accompanied by systemic symptoms, with the eruption of multiple sterile pustules over an area of erythema, associated or not with the form of plaque psoriasis. Epidemiological data on disease are limited, but a global prevalence is estimated at around 1-7 cases per million people, affecting mainly females, with a higher incidence in the fourth and fifth decades of life. Exacerbations are marked by varying degrees of inflammation and systemic symptoms and have an unpredictable evolution. Hyperactivity of the interleukin-36 (IL-36) inflammatory pathway was discovered as the main pathway responsible for causing the disease. Recently, the active substance spesolimab has shown excellent results in the treatment of GPP, with a mechanism of blocking IL-36 receptor activation, leading to the suppression of pro-inflammatory and profibrotic pathways in inflammatory skin and intestinal diseases.
format Article
id doaj-art-8b4ebf12212544cab6d9ad60d04dc25b
institution DOAJ
issn 2182-2395
2182-2409
language English
publishDate 2024-10-01
publisher Sociedade Portuguesa de Dermatologia e Venereologia
record_format Article
series Revista da Sociedade Portuguesa de Dermatologia e Venereologia
spelling doaj-art-8b4ebf12212544cab6d9ad60d04dc25b2025-08-20T02:49:34ZengSociedade Portuguesa de Dermatologia e VenereologiaRevista da Sociedade Portuguesa de Dermatologia e Venereologia2182-23952182-24092024-10-01824Serious generalized pustular psoriasis with evolution to plaque psoriasis: approach with spesolimabLiz S. Gea0Julia C. K. El Dib1Omar Algazal2Eduardo C.N. Constantino3Vera L. A. Nasser4João R. Antonio5Department of Dermatology, Hospital de Base, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, São José do Rio Preto, São Paulo, BrazilDepartment of Dermatology, Hospital de Base, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, BrazilDepartment of Dermatology and Department of Pathology, Hospital de Base, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, BrazilDepartment of Pathology, Hospital de Base, Faculdade de Medicina de São José do Rio Preto. São José do Rio Preto, São Paulo, BrazilDepartment of Dermatology and Department of Pathology, Hospital de Base, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, BrazilDepartment of Dermatology and Department of Pathology, Hospital de Base, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, São Paulo, BrazilGeneralized pustular psoriasis (GPP) is characterized by an acute and severe variant of psoriasis, often accompanied by systemic symptoms, with the eruption of multiple sterile pustules over an area of erythema, associated or not with the form of plaque psoriasis. Epidemiological data on disease are limited, but a global prevalence is estimated at around 1-7 cases per million people, affecting mainly females, with a higher incidence in the fourth and fifth decades of life. Exacerbations are marked by varying degrees of inflammation and systemic symptoms and have an unpredictable evolution. Hyperactivity of the interleukin-36 (IL-36) inflammatory pathway was discovered as the main pathway responsible for causing the disease. Recently, the active substance spesolimab has shown excellent results in the treatment of GPP, with a mechanism of blocking IL-36 receptor activation, leading to the suppression of pro-inflammatory and profibrotic pathways in inflammatory skin and intestinal diseases. https://www.portuguesejournalofdermatology.com/frame_eng.php?id=177Psoriasis. Pustular psoriasis. Generalized pustular psoriasis. Plaque psoriasis. Spesolimab. Anti interleukin-36.
spellingShingle Liz S. Gea
Julia C. K. El Dib
Omar Algazal
Eduardo C.N. Constantino
Vera L. A. Nasser
João R. Antonio
Serious generalized pustular psoriasis with evolution to plaque psoriasis: approach with spesolimab
Revista da Sociedade Portuguesa de Dermatologia e Venereologia
Psoriasis. Pustular psoriasis. Generalized pustular psoriasis. Plaque psoriasis. Spesolimab. Anti interleukin-36.
title Serious generalized pustular psoriasis with evolution to plaque psoriasis: approach with spesolimab
title_full Serious generalized pustular psoriasis with evolution to plaque psoriasis: approach with spesolimab
title_fullStr Serious generalized pustular psoriasis with evolution to plaque psoriasis: approach with spesolimab
title_full_unstemmed Serious generalized pustular psoriasis with evolution to plaque psoriasis: approach with spesolimab
title_short Serious generalized pustular psoriasis with evolution to plaque psoriasis: approach with spesolimab
title_sort serious generalized pustular psoriasis with evolution to plaque psoriasis approach with spesolimab
topic Psoriasis. Pustular psoriasis. Generalized pustular psoriasis. Plaque psoriasis. Spesolimab. Anti interleukin-36.
url https://www.portuguesejournalofdermatology.com/frame_eng.php?id=177
work_keys_str_mv AT lizsgea seriousgeneralizedpustularpsoriasiswithevolutiontoplaquepsoriasisapproachwithspesolimab
AT juliackeldib seriousgeneralizedpustularpsoriasiswithevolutiontoplaquepsoriasisapproachwithspesolimab
AT omaralgazal seriousgeneralizedpustularpsoriasiswithevolutiontoplaquepsoriasisapproachwithspesolimab
AT eduardocnconstantino seriousgeneralizedpustularpsoriasiswithevolutiontoplaquepsoriasisapproachwithspesolimab
AT veralanasser seriousgeneralizedpustularpsoriasiswithevolutiontoplaquepsoriasisapproachwithspesolimab
AT joaorantonio seriousgeneralizedpustularpsoriasiswithevolutiontoplaquepsoriasisapproachwithspesolimab